Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,388 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.
Saad A, Loren A, Bolaños-Meade J, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Elmariah H, Farag S, Gundabolu K, Gutman J, Ho V, Hoeg R, Horwitz M, Hsu J, Kassim A, Kharfan Dabaja M, Magenau J, Martin T, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Ninos C, Oliai C, Patel S, Randolph B, Schroeder M, Tzachanis D, Varshavsky-Yanovsky AN, Vusirikala M, Algieri F, Pluchino LA. Saad A, et al. Among authors: ho v. J Natl Compr Canc Netw. 2023 Feb;21(2):108-115. doi: 10.6004/jnccn.2023.0007. J Natl Compr Canc Netw. 2023. PMID: 36791762
Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.
Bolaños-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik L; Blood and Marrow Transplant Clinical Trials Network. Bolaños-Meade J, et al. Biol Blood Marrow Transplant. 2013 Mar;19(3):481-5. doi: 10.1016/j.bbmt.2012.12.003. Epub 2012 Dec 12. Biol Blood Marrow Transplant. 2013. PMID: 23247045 Free PMC article. Clinical Trial.
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolaños-Meade J, Alousi AM, Ferrara JL; Blood and Marrow Transplant Clinical Trials Network. Levine JE, et al. Lancet Haematol. 2015 Jan;2(1):e21-9. doi: 10.1016/S2352-3026(14)00035-0. Epub 2014 Dec 23. Lancet Haematol. 2015. PMID: 26687425 Free PMC article. Clinical Trial.
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB. Soiffer RJ, et al. J Clin Oncol. 2017 Dec 20;35(36):4003-4011. doi: 10.1200/JCO.2017.75.8177. Epub 2017 Oct 17. J Clin Oncol. 2017. PMID: 29040031 Free PMC article. Clinical Trial.
Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation.
Wu PA, Stern RS, Huang V, Liu KX, Chen CA, Tzachanis D, Joyce RM, Davis RB, Ho VT. Wu PA, et al. Among authors: ho vt. J Invest Dermatol. 2019 Mar;139(3):591-599. doi: 10.1016/j.jid.2018.08.025. Epub 2018 Oct 11. J Invest Dermatol. 2019. PMID: 30316899 Free article.
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Chen EC, Li S, Eisfeld AK, Luskin MR, Mims A, Jones D, Antin JH, Cutler CS, Koreth J, Ho VT, Gooptu M, Romee R, El-Jawahri A, McAfee SL, DeFilipp Z, Soiffer RJ, Chen YB, Fathi AT. Chen EC, et al. Transplant Cell Ther. 2021 Jun;27(6):479.e1-479.e7. doi: 10.1016/j.jtct.2021.02.028. Epub 2021 Feb 25. Transplant Cell Ther. 2021. PMID: 33840625 Free article.
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, Mims AS, DeFilipp Z, El-Jawahri A, McAfee SL, Brunner AM, Narayan R, Knight LW, Kelley D, Bottoms AS, Perry LH, Wahl JL, Brock J, Breton E, Ho VT, Chen YB. Fathi AT, et al. Blood Adv. 2022 Nov 22;6(22):5857-5865. doi: 10.1182/bloodadvances.2022008632. Blood Adv. 2022. PMID: 36150050 Free PMC article. Clinical Trial.
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, DeFilipp Z, El-Jawahri A, McAfee SL, Brunner AM, Amrein PC, Mims AS, Knight LW, Kelley D, Bottoms AS, Perry LH, Wahl JL, Brock J, Breton E, Marchione DM, Ho VT, Chen YB. Fathi AT, et al. Clin Cancer Res. 2023 Jun 1;29(11):2034-2042. doi: 10.1158/1078-0432.CCR-23-0182. Clin Cancer Res. 2023. PMID: 37014667 Clinical Trial.
1,388 results